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PROLIFERATION CONTROL
Cancer cells bear an indefinite proliferative capacity being able to
elude the commitment to terminal differentiation and quiescence
that normally regulate tissue homeostasis in the organism. To
achieve this property, tumour cells become independent from
external growth stimuli. For example, glioblastoma and sarcoma
cells produce their own growth factors, (PDGF) and transforming
growth factor a (TGF-a) respectively, that are normally produced
by stromal cells (Fedi et al, 1997). Similarly, melanoma cells
produce high levels of fibroblast growth factor 2 (FGF-2) and are
dependent on this growth factor for proliferation (Becker et al,
1989). On the other hand, the signalling pathways that are
involved in the transduction of mitogenic stimuli are often consti-
tutively activated in tumour cells, either by overexpression or by
mutation of signal transduction molecules. Examples are the up-
regulated expression of growth-factor receptors, such as epidermal
growth factor (EGF) receptor or HER-2/neu (Yarden and Ullrich,
1988). Moreover, tyrosine-kinase receptors, such as EGF receptor,
are frequently found mutated or truncated in a way that they are
constitutively active independently from ligand binding (Fedi
et al, 1997). Finally, 25% of human tumours present activating
mutations in ras, resulting in persistent signal transduction via the
MAP kinase pathway, the PI-3 kinase pathway, and possibly other
downstream effector pathways. Nonetheless, the transforming
potential of ras often depends on the cell type and possibly on its
expression levels. For example, in primary cells introduction of an
activated form of ras or constitutive activation of the Raf/MAP
kinase pathway induces cell senescence instead of proliferation
(Serrano et al, 1997; Lin et al, 1998; Zhu et al, 1998). In contrast,
in tumour-prone INK4a-deficient mice expression of an activated
Ha-ras is sufficient to induce melanoma formation (Chin et al,
1999b). Notably, the maintenance of the transformed state is
dependent on ras activity, since tumour growth is reversed when
expression of the oncogene is abolished. Similarly to ras, induc-
tion of c-myc expression in skin or T lymphocytes leads to
neoplasia in a reversible fashion (Felsher and Bishop, 1999;
Pelengaris et al, 1999). These experiments indicate that the sole
activation of an oncogene can instruct cells to proliferate and
prevent them from differention, growth arrest, or apoptosis.
Nonetheless, tumour cells seem to retain the capability of
returning to normal regulatory responses, when the oncogene is
inactivated. In contrast to these results, SV40 T antigen-mediated
transformation of pancreatic b-cells could not be reversed after a
certain time point (Ewald et al, 1996). These experiments solicit
questions about the number and nature of additional genetic or
epigenetic changes that render tumour cells irreversibly malignant.
Most signal transduction pathways directly or indirectly affect
cell cycle regulation, and tumour cells achieve the capability to
indefinitely proliferate also by directly de-regulating cell cycle
control. Such events mainly involve functional changes in the
tumour suppressor retinoblastoma (pRb) and components that are
affected by its function. In many cancer types and experimental
tumours, pRb itself is disabled, for example by mutation or
deletion of the gene or by interaction with viral oncoproteins
(SV40 T antigen, human papilloma virus E7, adenovirus E1A).
Alternatively, the function of molecules that act in the pRb
pathway are frequently impaired. For example, the gene for the
cyclin dependent kinase (cdk)-inhibitor p16 is often mutated or
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1998). These changes allow cancer cells to enter the cell cycle, to
maintain its progression and to escape growth-arrest signals.
A novel pathway for the onset of tumour cell proliferation has
recently been discovered by studying the function of the tumour
suppressor adenomatous polyposis coli (APC), mainly in colon
cancer and melanoma development. APC is mutated in a heredi-
tary form of colon cancer, familial adenomatous polyposis (FAP),
and in sporadic forms of colon cancer which invariably leads to
hyperproliferation of colon crypt cells and to the formation of
polyps (Kinzler and Vogelstein, 1996; Polakis, 1997). It has been
demonstrated that APC plays a central role in Wnt signalling.
Among several other proteins APC binds b-catenin and exposes it
to glycogen synthase kinase 3b (GSK3b) which phosphorylates
b-catenin and earmarks it for ubiquitination and degradation by
the proteasome pathway. In case APC function is lost, b-catenin
accumulates in the cytoplasm. A subset of b-catenin is imported
into the nucleus where it binds members of the LEF-1/TCF tran-
scription factor family and activates transcription of target genes
(Bullions and Levine, 1998; Eastman and Grosschedl, 1999),
including c-myc and cyclin D1 (He et al, 1998; Shtutman et al,
1999; Tetsu and McCormick, 1999). These results revealed the
long awaited molecular connection between the loss of APC
function and tumour cell proliferation. The same outcome, i.e.
up-regulation of cyclin D1 and c-myc and thus the induction of
proliferation, is achieved in melanoma cells by mutations in
b-catenin that render it resistant to phosphorylation by GSK3b.
This results in constitutively up-regulated b-catenin/TCF-medi-
ated transcriptional activity (Korinek et al, 1997; Morin et al,
1997; Rubinfeld et al, 1997).
SURVIVAL SIGNALS
The activation of oncogenes, such as ras and c-myc, not only
induces proliferation and transformation but also an apoptotic
signal mediated by the tumour suppressor p53. The connection
between proliferation and the induction of apoptosis by p53 has
been recently elucidated (Sherr, 1998). Up-regulated expression of
c-myc induces the expression of p19/ARF which subsequently
binds and inactivates mdm-2, a proto-oncogene that mediates the
degradation of p53 (Zindy et al, 1998). Stabilization and accumu-
lation of p53 results in transcriptional activation of several p53
target genes, including the cell cycle inhibitor p21, the apoptosis
inducer bax and several other genes that are known to directly or
indirectly induce apoptosis. Moreover, tumour cell apoptosis is
also frequently induced by up-regulated expression of Fas ligand
which in turn binds to Fas receptor expressed on tumour cells
(Hueber et al, 1997). The apoptotic response to unscheduled
proliferation possibly constitutes a general defence mechanism to
prevent transformation (Sherr, 1998). This notion has not only
given further justification to the high percentage of p53 mutations
found in human cancer, but also has emphasized the importance of
escaping apoptosis for tumour growth. Tumour cells frequently
up-regulate the expression of anti-apototic genes, such as bcl-2, to
counteract induction and execution of apoptosis (Jaattela, 1999).
Alternatively, many tumour types acquire the expression of growth
factors, such as IGFs and PDGFs, which act as survival signals.
Growth factor-mediated survival has been first demonstrated in
vitro by transformation of fibroblasts; c-myc-expressing fibro-
blasts rapidly die upon serum-starvation and are rescued from
apoptosis by a number of growth factors, including IGFs, PDGF
and FGFs (Harrington et al, 1994). In vivo, the role of IGF-II as a
survival signal has been demonstrated in a transgenic mouse
model of b-cell carcinogenesis (Christofori et al, 1994). IGFs
mediate survival by binding their cognate receptor, the IGF-1
receptor, and the subsequent activation of PI-3 kinase and
PKB/Akt (Downward, 1998; Baserga, 1999). Curiously, PTEN, a
major tumour suppressor gene that is mutated in a large fraction of
human cancer types, is able to impair survival factor function
(Ali et al, 1999). PTEN, as a bifunctional phosphatase, is able to
dephosphorylate both phosphoserines on proteins and phos-
patidylinositol phosphates, thereby directly counteracting PI-3
kinase activity and thus the anti-apoptotic function of PKB/Akt
(Stambolic et al, 1998).
SENESCENCE
Growth inhibition and apoptosis are not the only mechanisms that
counteract tumour progression. Cells have also developed a
device, based on their telomere length, to count the number of cell
doublings. Normal cells, after a limited number of divisions
(60–70 for human cells) enter crisis and, as a result, arrest in cell
cycle and enter a senescent state. Telomerase, the enzyme that is
responsible to maintain proper telomere length, is not active in
normal somatic cells, however, its activity is found to be up-regu-
lated in approximately 80% of cancer cells (Holt and Shay, 1999),
prolonging their life span and allowing them to circumvent crisis
and senescence (Bodnar et al, 1998). This concept is best illus-
trated by experiments in which tumour-prone INK4a-deficient
mice were crossed with telomerase-deficient mice (mTR2/2). In
the absence of telomerase activity, tumour incidence was greatly
reduced (Greenberg et al, 1999), indicating that the gain of telo-
merase activity indeed favours tumour progression. On the other
hand, two observations contradict this conclusion and complicate
the evaluation of telomerase as a target for therapeutic interven-
tion. First, telomerase-deficient mice, when bred up to the sixth
generation, exhibit a significant tumour predisposition (Rudolph
et al, 1999). Secondly, embryonic fibroblasts deficient for both
p53 and telomerase have a higher transformation rate than
p53-deficient cells (Chin et al, 1999a). In both cases, the lack of
telomerase activity correlates with a high rate of chromosomal
damage and overall genomic instability. Telomere erosion is now
known to be recognized by DNA damage-sensing systems
resulting in the induction of p53 (Karlseder et al, 1999; Zhang
et al, 1999). Therefore, it can be speculated, that in the absence
of p53, cells do not arrest upon DNA damage and continue to
accumulate chromosomal abnormalities, thus promoting tumour
progression.
Co-operative effects
Several groups have attempted to define the minimum number of
alterations that lead to the transformation of human cells. The
results are contradictory. Weinberg and co-workers succeeded in
transforming normal human epithelial cells and fibroblasts with a
combination of SV40 T antigen (to inactivate the two tumour
suppressors p53 and pRb), human telomerase (hTERT) and
activated ras (Hahn et al, 1999). In contrast, a previous report has
shown that the combination of hTERT, human papillomavirus
E6/E7 oncoproteins (to inactivate p53 and pRb), and activated ras
is not sufficient to induce transformation of human primary cells
(Morales et al, 1999). The reason for this discrepancy is not clear,
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Tumour angiogenesis
Already in the 1960s, Folkman and co-workers suggested that
tumour growth critically depends on the formation of new blood
vessels (angiogenesis) (Folkman, 1990). Since then, it has been
demonstrated that the angiogenic process is the result of a fine
balance between inducers and inhibitors (Folkman, 1995; Hanahan
and Folkman, 1996). Hence, induction of tumour angiogenesis can
be caused by the up-regulation of angiogenic factors or by the loss
of inhibitors. Among the angiogenic factors, vascular endothelial
growth factor (VEGF-A) is frequently up-regulated during tumori-
genesis, and its involvement in tumour progression has been
repeatedly proven (Ferrara, 1999). Notably, expression of VEGF-
A is high in hypoxic tumour areas and it is promoted by the
hypoxia inducible factor 1a (HIF-1a), a transcription factor that
regulates many other hypoxia-induced genes (Semenza, 1999).
Many naturally occurring and experimentally designed angio-
genesis inhibitors have been reported (Bouck et al, 1996). Among
the endogenous angiostatic factors, thrombospondin-1 (TSP-1) has
been identified as a direct transcriptional target of the tumour
suppressor p53 (Dameron et al, 1994). By binding to its receptor
CD36 on endothelial cells, TSP1 activates at least two distinct
signal transduction pathways that lead to endothelial cell apoptosis
(Jimenez et al, 2000). By virtue of its protease activity TSP-1 is
also able to activate the latent form of TGF-b, known for its cyto-
static activity on endothelial cells (Crawford et al, 1998). Loss of
p53, therefore, also contributes to the onset of tumour angio-
genesis. A similar connection between p53 function and tumour
angiogenesis has been recently demonstrated. It has been shown
that p53 targets HIF-1a to degradation via mdm-2. Conversely,
upon loss of p53, HIF-1a is no more degraded, thus supporting
tumour angiogenesis and with it tumour growth (Ravi et al, 2000).
Of course, inhibition of tumour angiogenesis is a major therapeutic
opportunity, and many of the compounds that are able to interfere
with tumour angiogenesis are already in clinical trials (Ferrara and
Alitalo, 1999).
Invasion and metastasis
The final stages of tumour progression are characterized by the
invasion of tumour cells into their surrounding tissue and the
dissemination of tumour cells to form metastases in distant organs.
The molecular mechanisms underlying the cellular changes during
these events are still not fully understood, however, there is a
general consensus that cell-to-cell and cell-to-substrate inter-
actions have to be profoundly altered during these final stages.
E-cadherin is the prototypic cell–cell adhesion molecule
involved in the formation of adherens junctions in epithelia. It is
functionally inactivated in virtually all human epithelial cancers
(carcinomas) by gene deletion or mutation, promoter silencing and
proteolytic cleavage of the protein (Christofori and Semb, 1999).
Moreover, germline mutations in the E-cadherin gene predispose
patients to diffuse and poorly differentiated gastric cancer
(Guilford et al, 1998). Experiments with a transgenic mouse model
for pancreatic b-cell carcinogenesis have demonstrated that the
loss of E-cadherin is causally involved in the transition from a
benign to a malignant tumour stage (Perl et al, 1998). However, it
remains elusive how the loss of E-cadherin-mediated cell–cell
adhesion induces active tumour cell invasion and metastasis. Since
the functional E-cadherin cell adhesion complex, among other
proteins, also contains b-catenin, it is conceivable that upon loss of
E-cadherin function b-catenin is released, translocates to the
nucleus and together with LEF-1/TCF transcription factors
induces specific transcriptional programmes (Christofori and
Semb, 1999).
Mainly based on in vitro experiments in which forced expres-
sion of proteases or inhibition of their activity altered the invasive-
ness of tumour cells, proteases have been assumed to play a
functional role only in late stage tumour progression. Un-
expectedly, this scenario has changed. For example, the metallo-
protease matrilysin (MMP-7) is already expressed in the early
stages of human colorectal cancer (Fingleton et al, 1999) and has
been shown to be a direct target of the transcriptional complex
b-catenin/TCF (Crawford et al, 1999). Notably, intestinal tumori-
genesis in a mouse strain carrying a mutated allele of the APC
tumour suppressor gene (Min mouse) is dramatically repressed
in the absence of matrilysin (Wilson et al, 1997). Surprisingly,
expression of stromelysin-1 (MMP-3) in the mammary gland of
transgenic mice appears to be sufficient to induce full-blown
carcinogenesis, linking protease activity with tumour initiation and
possibly proliferation control (Sternlicht et al, 1999). On the other
hand, gelatinase A (MMP-2) and the uPA/uPAR system have been
shown to play an important role in tumour angiogenesis (Brooks
et al, 1998; Rabbani, 1998; Coussens et al, 1999). Thus, proteases
act at multiple stages during tumour development and therefore
offer valuable targets for therapeutic intervention.
Mutator phenotypes
As discussed above, most of the events involved in the progression
to cancer represent genetic (mutational) changes that directly
affect proliferation, survival and transformation of tumour cells.
However, changes in basic regulatory mechanisms, such as DNA
repair or DNA methylation, also affect neoplastic transformation
by accelerating tumour progression.
In patients with hereditary non-polyposis colorectal cancer
(HNPCC), most tumours show microsatellite instability (MIN).
Microsatellites are highly repetitive DNA sequences that are prone
to accumulate errors (mismatches) during DNA replication. In
HNPCC patients, the failure to repair these mismatches is due to
inactivating mutations in genes involved in mismatch repair, such
as MLH1 and MSH2 (Peltomaki and de la Chapelle, 1997).
Defects in the mismatch repair system can shift the spontaneous
mutation rate from 10–6 to 10–3–10–2, resulting in a so-called
mutator phenotype characterized by an increased frequency of
mutations in tumour suppressor genes and oncogenes. Indeed,
microsatellites have been found within the coding regions of genes
that are known to play important roles in cellular transformation,
including APC, TGF-b receptor II, IGF-2 receptor, TCF-4, bax
and the mismatch repair genes themselves (Duval et al, 1999;
Schwartz et al, 1999). A failure to repair replication errors within
these microsatellites invariably leads to a loss of the tumour
suppressing functions of these genes.
In contrast to the genetic instability caused by DNA repair
defects (MIN), chromosomal instability (CIN) is characterized by
chromosomal rearrangements, including large deletions, fusions
and translocations (Lengauer et al, 1998). CIN is easily recognized
in tumour cells by their aneuploid DNA content. On a molecular
level, a first report indicates a correlation between aneuploidy and
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during mitosis (Cahill et al, 1998), however, a causal role of these
mutations in tumour initiation is still unclear. Evidence for an
involvement of chromosomal instability in cancer comes from
studies on DNA repair in response to double-strand DNA breaks.
Breaks in the DNA double helix, caused for example by g-irradia-
tion, usually induce activation of p53 via the kinases ATM/ATR or
alternatively of the p53 family member p73 via ATM and c-abl,
resulting in growth arrest or apoptosis (Dasika et al, 1999). Several
molecules involved in this pathway, such as ATM, or proteins that
may be directly involved in the repair mechanisms, such as
BRCA-1 and -2, are known tumour suppressor genes that are
frequently lost in several types of cancer. Knock-out mice defi-
cient for any of these genes develop tumours that exhibit genomic
instability, including aneuploidy and chromosomal rearrange-
ments (Dasika et al, 1999). DNA breaks are not only induced by
defects in sister chromatid separation during mitosis or by DNA
damaging agents. There are, in fact, sites in the genome that show
high predisposition to DNA breaks (fragile sites). Coincidentally,
another tumour suppressor gene, FHIT, is localized within one of
these fragile sites, and errors in repairing DNA breaks are likely
the cause of deletions observed in the FHIT gene (Huebner et al,
1998).
Besides mutation or deletion, tumour suppressor genes can also
be disabled by silencing their promoters. Recent studies have
demonstrated that in many different tumour cell types CpG islands
in the promoter region of many tumour suppressor genes are
hypermethylated, thereby preventing their expression (Toyota and
Issa, 1999). The frequency of this CpG island methylator pheno-
type (CIMP) accounts for most of the tumour cases in which muta-
tions or chromosomal aberrations affecting tumour suppressor
genes could not be detected. Tumour suppressor genes that are
inactivated by CIMP include the von Hippel Lindau gene (VHL),
the cell cycle inhibitor p16/INK4a, and the cell adhesion molecule
E-cadherin (Herman, 1999). Curiously, the mismatch repair gene
MLH1 has also been found inactivated by hypermethylation,
suggesting that CIMP may lead to the MIN mutator phenotype
(Herman, 1999). Hypermethylation does not appear to be a
random process, since some promoters seem to be predisposed
(Herman, 1999). However, the molecular mechanisms by which
promoter hypermethylation is achieved and how its specificity is
acquired are not known. There is only indirect evidence that alter-
ations in DNA methylase (Mtase) activity could account for CIMP.
Mtase activity is frequently found to be increased in various
human malignancies, including colon cancer, haematopoietic
cancers and lung cancer (Toyota and Issa, 1999). Moreover, inhibi-
tion of Mtase activity in mice, that by mutation of the APC tumour
suppressor gene are predisposed to colon cancer (Min mice),
markedly reduced tumour incidence (Laird et al, 1995).
The general role of mutator phenotypes in carcinogenesis, in
particular in cancer types other than colon cancer, will be an
interesting issue for the future.
CONCLUSION
Although still in its early days, molecular cancer research has
accomplished extraordinary progress in the understanding of the
molecular mechanisms underlying tumour progression. In addition
to tumour cell lines in culture, transgenic mouse models of tumori-
genesis have been instrumental in deciphering the molecular
players causally involved in the transition from one tumour stage
to the next. Moreover, basic research has begun to integrate
knowledge about the role of exogenous stimuli, including environ-
mental, occupational and dietary influences, into molecular path-
ways involved in multistage tumorigenesis. Thus, it is exciting
times not only for the full understanding of how tumours develop
but also for the discovery of novel appropriate targets for
therapeutic intervention.
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